Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1763, Issue 9, 2006, Pages 958-968

  Lee, Eung Ryoung ^a   Kim, Jang Yong ^a   Kang, Yong Jin ^a   Ahn, Jae Yeon ^a   Kim, Jung Hyun ^a   Kim, Bong Woo ^a   Choi, Hye Yeon ^a   Jeong, Mi Young ^a   Cho, Ssang Goo ^a  

^a Konkuk University   (South Korea)

Author keywords

Akt; Apoptosis; DNA damaging drug; Doxorubicin; ERK; Etoposide

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; DNA; DOXORUBICIN; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL STRAIN 3T3; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; DRUG RESPONSE; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DNA DAMAGE; DOXORUBICIN; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; INDOLES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NIH 3T3 CELLS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 33748464742     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2006.06.006     Document Type: Article

References (54)

1. Makin G. Targeting apoptosis in cancer chemotherapy. Expert Opin. Ther. Targets 6 (2002) 73-84
2. Doroshow J.H., and Davies K.J. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J. Biol. Chem. 261 (1986) 3068-3074
3. Persons D.L., Yazlovitskaya E.M., Cui W., and Pelling J.C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res. 5 (1999) 1007-1014
4. Wang X., Martindale J.L., and Holbrook N.J. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275 (2000) 39435-39443
5. Yu R., Shtil A.A., Tan T.H., Roninson I.B., and Kong A.N. Adriamycin activates c-jun N-terminal kinase in human leukemia cells: a relevance to apoptosis. Cancer Lett. 107 (1996) 73-81
6. Kang Y.J., Zhou Z.X., Wang G.W., Buridi A., and Klein J.B. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J. Biol. Chem. 275 (2000) 13690-13698
7. Guise S., Braguer D., Carles G., Delacourte A., and Briand C. Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells. J. Neurosci. Res. 63 (2001) 257-267
8. Negoro S., Oh H., Tone E., Kunisada K., Fujio Y., Walsh K., Kishimoto T., and Yamauchi-Takihara K. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 103 (2001) 555-561
9. Dudek H., Datta S.R., Franke T.F., Birnbaum M.J., Yao R., Cooper G.M., Segal R.A., Kaplan D.R., and Greenberg M.E. Regulation of neuronal survival by the serine-threonine protein kinase. Akt Science 275 (1997) 661-665
10. Kauffmann-Zeh A., Rodriguez-Viciana P., Ulrich E., Gilbert C., Coffer P., Downward J., and Evan G. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385 (1997) 544-548
11. Kennedy S.G., Wagner A.J., Conzen S.D., Jordan J., Bellacosa A., Tsichlis P.N., and Hay N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 11 (1997) 701-713
12. Kulik G., Klippel A., and Weber M.J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol. 17 (1997) 1595-1606
13. Widmann C., Gibson S., Jarpe M.B., and Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol. Rev. 79 (1999) 143-180
14. Fan M., and Chambers T.C. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist. Updat. 4 (2001) 253-267
15. Cho S.G., Kim J.W., Lee Y.H., Hwang H.S., Kim M.S., Ryoo K., Kim M.J., Noh K.T., Kim E.K., Cho J.H., Yoon K.W., Cho E.G., Park H.S., Chi S.W., Lee M.J., Kang S.S., Ichijo H., and Choi E.J. Identification of a novel antiapoptotic protein that antagonizes ASK1 and CAD activities. J. Cell Biol. 163 (2003) 71-81
16. Ryoo K., Huh S.H., Lee Y.H., Yoon K.W., Cho S.G., and Choi E.J. Negative regulation of MEKK1-induced signaling by glutathione S-transferase Mu. J. Biol. Chem. 279 (2004) 43589-43594
17. Zhao Y., You H., Yang Y., Wei L., Zhang X., Yao L., Fan D., and Yu Q. Distinctive regulation and function of PI 3K/Akt and MAPKs in doxorubicin-induced apoptosis of human lung adenocarcinoma cells. J. Cell. Biochem. 91 (2004) 621-632
18. Lee E.R., Kang Y.J., Kim J.H., Lee H.T., and Cho S.G. Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J. Biol. Chem. 280 (2005) 31498-31507
19. Ling Y.H., Priebe W., and Perez-Soler R. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. Cancer Res. 53 (1993) 1845-1852
20. Skladanowski A., and Konopa J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem. Pharmacol. 46 (1993) 375-382
21. Zaleskis G., Berleth E., Verstovsek S., Ehrke M.J., and Mihich E. Doxorubicin-induced DNA degradation in murine thymocytes. Mol. Pharmacol. 46 (1994) 901-908
22. Hibi M., Lin A., Smeal T., Minden A., and Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 7 (1993) 2135-2148
23. Adler V., Franklin C.C., and Kraft A.S. Phorbol esters stimulate the phosphorylation of c-Jun but not v-Jun: regulation by the N-terminal delta domain. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 5341-5345
24. Wang T.H., Wang H.S., Ichijo H., Giannakakou P., Foster J.S., Fojo T., and Wimalasena J. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J. Biol. Chem. 273 (1998) 4928-4936
25. MacKinnon A.C., Waters C., Rahman I., Harani N., Rintoul R., Haslett C., and Sethi T. [Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) (antagonist G) induces AP-1 transcription and sensitizes cells to chemotherapy. Br. J. Cancer 83 (2000) 941-948
26. Mandlekar S., Yu R., Tan T.H., and Kong A.N. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res. 60 (2000) 5995-6000
27. Stadheim T.A., and Kucera G.L. c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells. Leuk Res. 26 (2002) 55-65
28. Osborn M.T., and Chambers T.C. Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J. Biol. Chem. 271 (1996) 30950-30955
29. Nemoto S., Xiang J., Huang S., and Lin A. Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase. J. Biol. Chem. 273 (1998) 16415-16420
30. Zechner D., Craig R., Hanford D.S., McDonough P.M., Sabbadini R.A., and Glembotski C.C. MKK6 activates myocardial cell NF-kappaB and inhibits apoptosis in a p38 mitogen-activated protein kinase-dependent manner. J. Biol. Chem. 273 (1998) 8232-8239
31. Communal C., Colucci W.S., and Singh K. p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against beta-adrenergic receptor-stimulated apoptosis. Evidence for Gi-dependent activation. J. Biol. Chem. 275 (2000) 19395-19400
32. Sanchez-Prieto R., Rojas J.M., Taya Y., and Gutkind J.S. A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res. 60 (2000) 2464-2472
33. Deschesnes R.G., Huot J., Valerie K., and Landry J. Involvement of p38 in apoptosis-associated membrane blebbing and nuclear condensation. Mol. Biol. Cell 12 (2001) 1569-1582
34. Hu X., Janssen W.E., Moscinski L.C., Bryington M., Dangsupa A., Rezai-Zadeh N., Babbin B.A., and Zuckerman K.S. An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism. Cancer Res. 61 (2001) 6290-6296
35. Dashti S.R., Efimova T., and Eckert R.L. MEK6 regulates human involucrin gene expression via a p38alpha- and p38delta-dependent mechanism. J. Biol. Chem. 276 (2001) 27214-27220
36. Cheng M., Sexl V., Sherr C.J., and Roussel M.F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 1091-1096
37. Lavoie J.N., L'Allemain G., Brunet A., Muller R., and Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 271 (1996) 20608-20616
38. Kawada M., Yamagoe S., Murakami Y., Suzuki K., Mizuno S., and Uehara Y. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15 (1997) 629-637
39. Lenferink A.E., Busse D., Flanagan W.M., Yakes F.M., and Arteaga C.L. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res. 61 (2001) 6583-6591
40. van den Brink M.R., Kapeller R., Pratt J.C., Chang J.H., and Burakoff S.J. The extracellular signal-regulated kinase pathway is required for activation-induced cell death of T cells. J. Biol. Chem. 274 (1999) 11178-11185
41. Basu S., Bayoumy S., Zhang Y., Lozano J., and Kolesnick R. BAD enables ceramide to signal apoptosis via Ras and Raf-1. J. Biol. Chem. 273 (1998) 30419-30426
42. Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F., Hamilton T.C., Tsichlis P.N., and Testa J.R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 9267-9271
43. Cheng J.Q., Ruggeri B., Klein W.M., Sonoda G., Altomare D.A., Watson D.K., and Testa J.R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3636-3641
44. Testa J.R., and Bellacosa A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10983-10985
45. Cheng J.Q., Jiang X., Fraser M., Li M., Dan H.C., Sun M., and Tsang B.K. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist. Updat. 5 (2002) 131-146
46. Arlt A., Gehrz A., Muerkoster S., Vorndamm J., Kruse M.L., Folsch U.R., and Schafer H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22 (2003) 3243-3251
47. Knuefermann C., Lu Y., Liu B., Jin W., Liang K., Wu L., Schmidt M., Mills G.B., Mendelsohn J., and Fan Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22 (2003) 3205-3212
48. Yuan Z.Q., Feldman R.I., Sussman G.E., Coppola D., Nicosia S.V., and Cheng J.Q. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J. Biol. Chem. 278 (2003) 23432-23440
49. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., Hortobagyi G.N., Hung M.C., and Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 (2004) 117-127
50. Plo I., Bettaieb A., Payrastre B., Mansat-De Mas V., Bordier C., Rousse A., Kowalski-Chauvel A., Laurent G., and Lautier D. The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines. FEBS Lett. 452 (1999) 150-154
51. Nakashio A., Fujita N., Rokudai S., Sato S., and Tsuruo T. Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res. 60 (2000) 5303-5309
52. Tang D., Okada H., Ruland J., Liu L., Stambolic V., Mak T.W., and Ingram A.J. Akt is activated in response to an apoptotic signal. J. Biol. Chem. 276 (2001) 30461-30466
53. Zhou B., Wang Z.X., Zhao Y., Brautigan D.L., and Zhang Z.Y. The specificity of extracellular signal-regulated kinase 2 dephosphorylation by protein phosphatases. J. Biol. Chem. 277 (2002) 31818-31825
54. Lee K., and Esselman W.J. Inhibition of PTPs by H(2)O(2) regulates the activation of distinct MAPK pathways. Free Radical Biol. Med. 33 (2002) 1121-1132